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Abstract
Background: Trypanosoma brucei, the causative agent of Human African Trypanosomiasis (HAT), expresses two proteins
with homology to human glycogen synthase kinase 3b (HsGSK-3) designated TbruGSK-3 short and TbruGSK-3 long. TbruGSK-
3 short has previously been validated as a potential drug target and since this enzyme has also been pursued as a human
drug target, a large number of inhibitors are available for screening against the parasite enzyme. A collaborative industrial/
academic partnership facilitated by the World Health Organisation Tropical Diseases Research division (WHO TDR) was
initiated to stimulate research aimed at identifying new drugs for treating HAT.
Methodology/Principal Findings: A subset of over 16,000 inhibitors of HsGSK-3 b from the Pfizer compound collection was
screened against the shorter of two orthologues of TbruGSK-3. The resulting active compounds were tested for selectivity
versus HsGSK-3b and a panel of human kinases, as well as in vitro anti-trypanosomal activity. Structural analysis of the
human and trypanosomal enzymes was also performed.
Conclusions/Significance: We identified potent and selective compounds representing potential attractive starting points
for a drug discovery program. Structural analysis of the human and trypanosomal enzymes also revealed hypotheses for
further improving selectivity of the compounds.
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Introduction
Human African trypanosomiasis (HAT) and the lack of
effective therapy constitute a health concern in 36 countries of
sub-Saharan Africa [1]. The disease affects predominantly poor
populations and transmission has been attributed to exposure
during activities such as agriculture, animal husbandry, or
hunting [2], which are the major means of livelihood in endemic
regions. Following acute infection, the disease progresses to a
chronic phase ultimately with invasion of the brain. This can
happen within a month of initial infection, or alternatively can
take years, depending on the parasite sub-species [3]. Four
drugs, Eflornithine, Suramin, Pentamidine and Melarsoprol, are
currently licensed for the treatment of HAT [4,5]. Unfortu-
nately, these are toxic and difficult to administer, limiting
therapeutic choices [6]. Thus, new therapies for HAT are
urgently needed.
Protein kinases, estimated to represent over 30% of all drug
discovery programs, remain one of the most studied drug targets
for a number of human and animal diseases [7–10]. More than
500 protein kinases have thus far been identified, many of which
are linked to disease processes [11]. Of particular interest here is
a serine/threonine glycogen synthase kinase -3 (GSK-3), which
plays a role in the regulation of glycogen metabolism [12,13],
WNT signaling [14], cell cycle regulation [15,16] and other
processes. HsGSK-3 has been investigated as a drug target for
several diseases including Alzheimer’s disease [17], neurode-
generation and oncogenesis [18]. Two isoforms of GSK-3 exist
in human cells, HsGSK-3 alpha and HsGSK-3 beta. These
human isoforms display a high degree of sequence identity with
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Asp133 in HsGSK-3 beta) in the ATP binding domain [19,20].
Previous studies [21] demonstrated that the causative agent of
HAT, Trypanosoma brucei, expresses two proteins (TbruGSK-3 short
and TbruGSK-3 long) with homology to HsGSK-3. The shorter
protein isoform was shown to be essential for parasite growth and
viability and inhibitors of TbruGSK-3 short were found to kill
mammalian-stage T. brucei. The authors concluded that evolu-
tionary variations in the ATP binding domain of TbruGSK-3
short, relative to HsGSK-3 beta, might allow for designing parasite
selective inhibitors.
HAT drug development is challenged by the disproportionately
small commercial interest and investment in developing new anti-
parasite agents relative to other human diseases like cancer [22].
Thisstudy involved a collaborative Public-Private Partnership (PPP)
facilitated by WHO TDR between researchers at University of
Washington, USA, University of Antwerp, Belgium, and Pfizer
Global Research Development, Sandwich, UK, to find specific
inhibitors of T.brucei using a target-based high throughput screening
(HTS) approach. This is an example of how drug development for
neglected diseases can be stimulated by the PPP approach.
A panel of 16,540 putative inhibitors previously associated with
projects at Pfizer targeting HsGSK-3 was screened against the
recombinant TbruGSK-3 short. Selected hits were counter-
screened against HsGSK-3b. Kinase panel specificity and anti-
parasitic screening were also conducted. Compounds identified in
this study provide useful starting points for further chemical
optimisation.
Methods
T. brucei GSK-3 short screening
Recombinant TbruGSK-3 short (accession number
Tb10.161.3140) was produced at the University of Washington
[21] and shipped to Pfizer, Sandwich, UK for testing. Kinase-Glo
reagent (Promega) was used as previously described [23]. This
luciferase coupled assay, which provides a luminescent quantifi-
cation of ATP consumed during the kinase reaction, was modified
to a 384-well plate screening format. A selected library of 16,540
compounds comprising known HsGSK-3 beta inhibitors and close
structural analogues was screened at 10 mM final assay concen-
tration. Assay plates were prepared by dispensing 0.2 mLo f
compound (dissolved in 100% DMSO) from master plates into
white 384-well plates (Greiner bio one). Primary screening was
conducted in a 20 mL reaction volume. Enzyme was added to each
well to a final concentration of 3.8 nM in a volume of 10 ml using a
Multidrop Combi dispenser (Thermo Scientific) and the plates
were incubated for 15 minutes at room temperature (RT).
Glycogen synthase peptide 2 (BioGSP2; Sigma) and ATP, were
dissolved in 20% acetonitrile and 1 M Tris-HCl pH 7.6
respectively, then diluted in assay buffer to a final concentration
of 3.2 mM BioGSP2 and 2 mM ATP. The assay buffer consisted of
25 mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM DTT, 0.1 mg/
mL BSA, 2 U/mL Heparin and 10 mM EDTA. The reaction was
initiated by adding 10 mL of the substrate mixture to each well and
allowed to proceed at RT for 2 h. Twenty microlitres of Kinase-
Glo reagent was added to quench the reaction. Luminescence was
measured after 1 h at a 100 millisecond/well integration time
using the Acquest Multimode plate reader (Molecular Devices).
Each plate included a positive control (4 mM GW8510, Sigma)
and negative control (1% DMSO). Hit compounds were further
titrated using a through-plate IC50 format with a maximum
concentration of 25 mM. The data was analysed using Pfizer
SIGHTS software and visualised using Spotfire software (TIBCO).
Five separate 384-well plates were screened in duplicate to assess
the assay reproducibility.
Human GSK-3 beta screening
Human GSK-3 beta inhibition data (IC50) for many of the
compounds were recovered from Pfizer data files. If historical
data were not available, the compounds were tested in an assay
using 10 nM HsGSK-3 beta (Invitrogen) using Omnia Kinase
Assay (Invitrogen) according to the manufacturer’s instructions.
T h er e a c t i o nv o l u m ew a s2 0mL and a range of compound
concentrations were tested, up to a maximum of 40 mM.
Briefly, 5 mlo fHsG S K - 3b e t aw a sd i s p e n s e di n t ob l a c k3 8 4
assay plates (Greiner bio one) containing 0.2 mlo fc o m p o u n d s .
The enzyme was incubated with the compounds for 15 minutes
at 30uCt h e n1 5ml of substrate mixture was added to each well
to commence the reaction. The substrate mixture consisted of
2 mLe a c ho f2 6kinase reaction buffer, 10 mMO m i n ap e p t i d e
substrate, 0.2 mM DTT and 10 mMA T P ,a n d7mLo fu l t r a
pure water. The reaction was allowed to proceed for 30 minutes
at 30uC. Increase in fluorescence levels indicating peptide
phosphorylation by the enzyme was monitored using an
Envision (PerkinElmer) with lex 360/lem 485 nm and the
data were analysed using Pfizer software SIGHTS and Spotfire
(TIBCO).
Antiparasitic and kinase panel screening
Compounds with TbruGSK-3 short IC50,100 nM were tested
for their ability to inhibit the proliferation of T. brucei (blood stage
form). Cytotoxicity testing against human fetal lung fibroblast
MRC-5 cell line was also performed. Both assays were carried out
with compound concentrations up to 64 mM at the Laboratory for
Microbiology, Parasitology and Hygiene, University of Antwerp
(www.ua.ac.be). Briefly, T. brucei trypomastigotes (Squib-427
strain, suramin-sensitive) were cultured in Hirumi-9 medium
supplemented with 10% fetal calf serum at 1.5610
4 trypomasti-
gotes per well. Following 72 hours incubation, parasite growth was
assessed fluorimetrically by addition of resazurin. For cytotoxicity
Author Summary
Over 60 million people in sub-Saharan Africa are at risk of
infection with the parasite Trypanosoma brucei which
causes Human African Trypanosomiasis (HAT), also known
as sleeping sickness. The disease results in systemic and
neurological disability to its victims. At present, only four
drugs are available for treatment of HAT. However, these
drugs are expensive, limited in efficacy and are severely
toxic, hence the need to develop new therapies. Previous-
ly, the short TbruGSK-3 short has been validated as a
potential target for developing new drugs against HAT.
Because this enzyme has also been pursued as a drug
target for other diseases, several inhibitors are available for
screening against the parasite enzyme. Here we present
the results of screening over 16,000 inhibitors of human
GSK-3b (HsGSK-3) from the Pfizer compound collection
against TbruGSK-3 short. The resulting active compounds
were tested for selectivity versus HsGSK-3b and a panel of
human kinases, as well as their ability to inhibit
proliferation of the parasite in vitro. We have identified
attractive compounds that now form potential starting
points for drug discovery against HAT. This is an example
of how a tripartite partnership involving pharmaceutical
industries, academic institutions and non-government
organisations such as WHO TDR, can stimulate research
for neglected diseases.
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4 MRC-5 cells/well were seeded onto the test plates
containing the pre-diluted compounds and incubated at 37uC with
5% CO2 for 72 hours. Cell viability was determined fluorime-
trically after addition of resazurin [24,25]. Single point kinase
panel screening was also conducted on selected compounds at
10 mM by Invitrogen (www.Invitrogen.com) and University of
Dundee, UK (www.dundee.ac.uk).
Modelling
The crystal structure of human GSK-3 beta complexed with
staurosporine (pdb entry 1q3d) was used as the basis for modelling
work. Selected compounds were docked into the crystal structure
of HsGSK-3 beta on the basis of binding modes of related known
ligands. The binding-site residues were aligned and the residues
that differ between human and TbruGSK-3 in the catalytic pocket
were highlighted with different colours. Images were created using
the Pfizer molecule-modelling package MoViT.
Results
Assay Performance
A high throughput 384-well assay was developed for Tbru GSK-
3 short which measures ATP depletion following phosphorylation
of the peptide substrate BioGSP-2. The previously identified
inhibitor of TbruGSK-3 short, GW8510 [21], was used as a
positive control. The assay yielded Z and Z’ scores of 0.2 and 0.8,
respectively, indicating excellent quality [26]. Assay reproducibil-
ity in HTS format was confirmed by duplicate testing of 5 separate
384-well plates which produced an identical number of hits
(Figure 1A).
GSK-3 Enzyme Screening
A collection of 16,540 compounds targeting HsGSK-3 beta
were selected from Pfizer compound library and screened against
TbruGSK-3 short at a concentration of 10 mM. In order to
capture all potential actives, compounds conferring above 40%
inhibition were considered hits, giving an overall hit rate of 8.6%
(Figure 1B). Hits were titrated in the screening assay, revealing
1,317 hits with IC50,25 mM. Of these confirmed hits, 362
compounds had IC50,1 mM and 35 compounds had
IC50,100 nM. The IC50 data against HsGSK-3 beta were either
recovered from Pfizer records or the titration was conducted on
selected compounds. A comparative analysis of inhibitor
potencies between TbruGSK-3 short and HsGSK-3 beta is
presented in Figure 1C. A majority of the compounds exhibited
greater potency against the human enzyme which is not
surprising, since the initial library was primarily made up of
compounds that had been optimized for binding to HsGSK-3
beta. Compounds were clustered with an in-house algorithm that
carries out single-linkage clustering, whereby any pair of
compounds sharing a Tanimoto similarity value of 0.7 (calculated
using Daylight fingerprints) were placed in the same cluster
Figure 1. Screening results. (A) Verification of data reproducibility generated from duplicate testing of 5 separate 384-well plates. (B) Histogram
plot showing distribution of hit compounds (black bars). (C) Plot of TbruGSK-3 short pIC50 against HsGSK-3 pIC50 revealing TbruGSK-3 short selective
compounds. Points are shaded by cluster ID and shaped by iteration, where squares are the original hits and stars are the near neighbours that were
subsequently picked. pIC50 is -log IC50 where 9=1 nM and 6=1 mM.
doi:10.1371/journal.pntd.0001017.g001
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expanded by selecting near neighbour analogues from the Pfizer
compound libraries and further titrating them against both
HsGSK-3 beta and TbruGSK-3 short. Two compounds, 0181276
and PF-04903528, were found to show 7-fold selective inhibition
of TbruGSK-3 short compared to HsGSK-3 beta (Table 1 and
Figure 2).
Whole Parasite Screening
Seventeen compounds with TbruGSK-3 short IC50 values of
,100 nM (regardless of selectivity) were tested for their ability to
inhibit the proliferation of mammalian-stage T. brucei. Specificity for
the parasite was investigated by testing against the human fetal lung
fibroblast MRC-5 cell line (Table 1 and Figure 2). Ten compounds
showed in-vitro inhibition of T. brucei proliferation with EC50so f
,1 mMa n d6h a dE C 50s of 1–3 mM. Several of the most potent
compounds also showed potent inhibition of the MRC5 cell line.
However, six compounds showed at leasta 5-fold window between T.
brucei activity and activity on MRC5 cells, particularly CE-317112
whichhad35-foldselectivity(Table1).Ingeneral,potentinhibitionof
TbruGSK-3 enzyme activity correlated with potent activity against
the whole parasite. However, CE-160042 which was a potent
inhibitor of TbruGSK-3 enzyme activity, showed no inhibition of the
whole parasite (EC50 .25 mM). We subsequently discovered that this
compound showed no detectable cell permeability in a standard
CaCo2 cell flux assay used routinely in drug discovery (data not
shown) and therefore the lack of activity is most likely due to the
compound failing to reach the target within the parasite.
Human Kinase Specificity
Human kinase inhibitors often inhibit more than one kinase
leading to safety issues. In order to understand the kinase
inhibition profile of TbruGSK-3 inhibitors, 13 of the compounds
were screened at 10 mM against a panel of approximately 40
human kinases. One of the compounds, CE-160042, was highly
specific and only inhibited HsGSK-3 beta (Figure 3). PF-4279731
and 0180532 were also relatively specific showing .50%
inhibition of only 2 and 4 other kinases, respectively. The
remaining compounds were active against more than 10 other
kinases.
Modelling
Previous modelling of the Tbru GSK-3 active site identified a
number of residues that differ between the human and parasite
enzyme that could potentially be exploited to achieve selective
inhibition. Using the published enzyme structures [21], the
predicted binding modes of two of our compounds were
examined (Figure 4). This demonstrated that of the previously
reported binding site differences, only one, T.bru M101/Hs
L132 is in close proximity to the compound binding site and
therefore is likely to be the key residue for achieving selectivity.
The modelling suggests that greater selectivity could be
achieved by making compounds with substituents that have
improved interaction with meth i o n i n ec o m p a r e dt ol e u c i n ea t
this position.
Discussion
We have exploited knowledge of the essentiality of TbruGSK-
3 short and the availability of a large number of HsGSK-3b
inhibitors to initiate a drug discovery program for Human
African Trypanosomiasis. Over 16,000 compounds were
screened against TbruGSK-3 short isoform and compounds of
interest were tested against HsGSK-3 beta, whole parasites and
human cells. Specificity against a panel of approximately 40
Table 1. GSK-3 Enzyme, Antiparasitic and cytotoxicity testing (values in mM).
Compound ID Tbru GSK-3 short IC50 HSGSK-3 IC50 Tbru parasite EC50 MRC-5 EC50
CE-317112 0.099 0.003 1.14 39.40
PF-01242377 0.061 0.132 0.13 1.18
CE-160042 0.142 0.032 .25 NT
PF-04995633 0.097 NT 0.65 0.82
PF-04936572 0.091 NT 0.21 0.23
CE-325692 0.065 0.002 0.64 4.67
PF-00744923 0.070 ,1.000* 0.13 0.13
AG-02449 0.069 NT 0.13 0.62
PF-04903528 0.032 0.236 1.13 1.13
PF-02368935 0.019 ,1.000* 0.13 0.13
PF-00305135 0.067 0.003 2.45 0.93
CE-309608 0.021 0.046 2.69 16.00
PF-00956933 0.057 ,1.000* 0.13 2.17
AG-024290 0.062 0.173 0.13 0.13
PF-04279731 0.062 0.001 1.23 1.47
CE-324998 0.093 0.001 0.23 1.22
CE-325011 0.094 0.005 1.05 2.32
0181276 0.600 4.29 NT NT
0180532 7.27 0.06 NT NT
Values are a mean of at least 2 replicates. NT = not tested due to limited compound availability.
*Due to limited compound availability, these compounds were only tested at a single concentration of 1 mM and showed .50% inhibition at this concentration.
doi:10.1371/journal.pntd.0001017.t001
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with approximately 7-fold selectivity for TbruGSK-3 short over
HsGSK-3 beta: PF-04903528 and 0181276. One of these,
0181276 was also relatively specific against the wider human
kinase panel. CE-160042 was not selective against the parasite
enzyme, but was completely selective for HsGSK-3 beta and
showed no significant inhibition of any other kinases. In
addition, CE-317112 showed a 35-fold safety window relative
to the cytotoxicity control. Together, these compounds repre-
sent an attractive starting point for medicinal chemistry with a
focus on further improving selectivity for a drug discovery
program.
Using structural modelling, we have shown that improved
selectivity may be possible by exploiting the T.bru M101/Hs
L132 active site difference. Given that this is a relatively small
difference, highly selective compounds may be difficult to
obtain, however it is encouraging that our intitial screening
has identified compounds with 7-fold selectivity. Previous
Figure 2. Chemical structures of the inhibitors.
doi:10.1371/journal.pntd.0001017.g002
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www.plosntds.org 5 April 2011 | Volume 5 | Issue 4 | e1017Figure 3. Kinase selectivity screening. Compounds were screened in one of two kinase panels at a concentration of 10 mM. The degree of
inhibition of each kinase is indicated by shading as follows: white ,29% inhibition, light grey 30-49% inhibition, dark grey 50-69% inhibition, black
.70% inhibition. Key to compounds: (1) 0181276, (2) CE-160042, (3) 0180532, (4) PF-4903528, (5) PF-4936572, (6) PF-4995633, (7) AG-24290, (8) PF-
4279731, (9) CE-317112, (10) PF-1242377, (11) PF-744923, (12) PF-2368935, (13) PF-956933. NT = not tested.
doi:10.1371/journal.pntd.0001017.g003
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causes no significant changes in body weight, food consump-
tion or any associated adverse effects, as judged by histopa-
thology or blood chemistry analyses [27,28]. Therefore, low
levels of specificity may be tolerated. However, mouse knock-
out studies of GSK-3 beta have shown embryonic lethality due
to liver degeneration and changes in bone development
[29,30]. Consequently, non-selective inhibitors would not be
safe for use in pregnant women, infants and young children.
Therefore, selective inhibitors of the parasite enzyme would be
highly desirable and the availability of the GSK-3 structural
models provides a powerful tool for structure assisted
compound design which could guide synthesis of more
selective compounds, based on the initial 7-fold selective
c o m p o u n d sw eh a v ei d e n t i f i e d .
This early drug discovery collaboration was facilitated by
WHO TDR and demonstrates the power of such public
private partnerships in bringing together the drug discovery
expertise of pharma companies, the detailed target knowledge
from academia and access to parasite biological assays from
expert screening centers to accelerate drug discovery for
neglected tropical diseases. Our most promising compounds
Figure 4. Modelling of the binding-site residues with putative inhibitors. Compounds (orange) docked into the catalytic domain of the
crystal structure of HsGSK3 beta in their binding modes. A: CE-317112 shows preference for HsGSK-3 beta. B: PF-4903528 shows preference for
TbruGSK-3 short. The residues that differ between human and TbruGSK-3 short are shown in magenta, with only L132M (top centre of the image)
directly lining the pocket. Images were created using the Pfizer molecule-modelling package MoViT.
doi:10.1371/journal.pntd.0001017.g004
T. brucei Glycogen Synthase Kinase-3 Inhibitors
www.plosntds.org 7 April 2011 | Volume 5 | Issue 4 | e1017are disclosed to accelerate the pace of drug development for
HAT.
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